Abstract
Unbiased proteomic analyses of cell fractions, interactomes and protein modifications coupled with more targeted approaches are adding to an impressive database of the signalling pathways in platelets. In addition to the well characterised receptors that are known to exist on the platelet surface, platelet proteomic studies continue to expose novel transmembrane proteins including CD148, CLEC-2, Eph kinases and Ephrins, Frizzled-4 and -6, G6b, HIP-55, HSP47, LRP5/6 and PEAR-1. In turn identification of novel platelet receptors has led to the discovery of new platelet signalling pathways such as the collagen/CLEC-2 receptor pathway, as well as the canonical WNT pathway. This review focuses on the canonical WNT pathway, providing background information to WNT ligands, receptors and signalling pathways and then focusing on canonical WNT signalling in anucleate platelets, where the suppression of platelet activity and adhesion by its ligand, Wnt-3a has recently been demonstrated.
Keywords: Canonical WNT signalling, frizzled receptors, novel signalling pathways, novel transmembrane proteins, Platelets, β-catenin, Thromboxane, Adenosine diphosphate, Ephrins, mass spectrometry, transmembrane receptor, CLEC-2
Current Proteomics
Title: Novel Platelet Signalling Pathways Identified via Proteomics
Volume: 8 Issue: 3
Author(s): Patricia B. Maguire, Brian M. Steele and Desmond J. Fitzgerald
Affiliation:
Keywords: Canonical WNT signalling, frizzled receptors, novel signalling pathways, novel transmembrane proteins, Platelets, β-catenin, Thromboxane, Adenosine diphosphate, Ephrins, mass spectrometry, transmembrane receptor, CLEC-2
Abstract: Unbiased proteomic analyses of cell fractions, interactomes and protein modifications coupled with more targeted approaches are adding to an impressive database of the signalling pathways in platelets. In addition to the well characterised receptors that are known to exist on the platelet surface, platelet proteomic studies continue to expose novel transmembrane proteins including CD148, CLEC-2, Eph kinases and Ephrins, Frizzled-4 and -6, G6b, HIP-55, HSP47, LRP5/6 and PEAR-1. In turn identification of novel platelet receptors has led to the discovery of new platelet signalling pathways such as the collagen/CLEC-2 receptor pathway, as well as the canonical WNT pathway. This review focuses on the canonical WNT pathway, providing background information to WNT ligands, receptors and signalling pathways and then focusing on canonical WNT signalling in anucleate platelets, where the suppression of platelet activity and adhesion by its ligand, Wnt-3a has recently been demonstrated.
Export Options
About this article
Cite this article as:
B. Maguire Patricia, M. Steele Brian and J. Fitzgerald Desmond, Novel Platelet Signalling Pathways Identified via Proteomics, Current Proteomics 2011; 8 (3) . https://dx.doi.org/10.2174/157016411797247503
DOI https://dx.doi.org/10.2174/157016411797247503 |
Print ISSN 1570-1646 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6247 |
Call for Papers in Thematic Issues
Mass spectrometry data acquisition and analysis for proteomics
The Thematic Issue on "Mass spectrometry data acquisition and analysis for proteomics" aims to explore the latest advancements and challenges in the field of proteomics through the lens of mass spectrometry. Proteomics, the large-scale study of proteins and their functions, plays a crucial role in understanding various biological processes and ...read more
Peptides: State-of-Art and Commercialisation Hurdles
The Editors of the Current Proteomics (CP) journal are highly privileged to welcome scientists to submit their scientific research and review articles to be considered for publication in the upcoming thematic issue. The topics should cover various aspects of peptides in regard to their synthetic methodologies, formulation approaches, pharmacological challenges, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Adverse Effects and Safety of Etirinotecan Pegol, a Novel Topoisomerase Inhibitor, in Cancer Treatment: A Systematic Review
Current Cancer Therapy Reviews The Interaction of GLUT1 and FOXM1 Leads to a Poor Prognosis in Colorectal Cancer
Anti-Cancer Agents in Medicinal Chemistry Syncytin and GCMa: Key Regulators in Human Placental Physiology and in Pre-Eclampsia
Current Women`s Health Reviews Recent Patents on Live Bacteria and their Products as Potential Anticancer Agents
Recent Patents on Anti-Cancer Drug Discovery Recent Developments in Targeted Therapies of the RAF-MEK and PI3KAKT Pathways in Cancer Treatment
Current Cancer Therapy Reviews QSAR Study on MHC Class I A Alleles Based on the Novel Parameters of Amino Acids
Protein & Peptide Letters Ribozymes in the Age of Molecular Therapeutics
Current Molecular Medicine Cholesterol-Rich Nanoemulsions (LDE) for Drug Targeting of Cholesteryl-Succinyl- 5-Fluorouracil Conjugate
Current Nanoscience Review of Childhood Obesity (Balar Athidhoola Rogam) in Traditional Siddha Indian Medicine
Current Traditional Medicine CXXC5 Associates with Smads to Mediate TNF-α Induced Apoptosis
Current Molecular Medicine Nitrosative Stress as a Mediator of Apoptosis: Implications for Cancer Therapy
Current Pharmaceutical Design Nitric Oxide: Cancer Target or Anticancer Agent?
Current Cancer Drug Targets The Urokinase Plasminogen Activator System: Role in Malignancy
Current Pharmaceutical Design The Epigenetic Origin of Aneuploidy
Current Genomics Prolyl-Specific Peptidases and Their Inhibitors in Biological Processes
Current Chemical Biology Editorial [Hot Topic:Angiogenesis Agents(Executive Editor: Cezary Marcinkiewicz)]
Current Pharmaceutical Design Pharmacokinetics-Pharmacology Disconnection of Herbal Medicines and its Potential Solutions with Cellular Pharmacokinetic-Pharmacodynamic Strategy
Current Drug Metabolism The Role of Aryl Hydrocarbon Receptor-Regulated Cytochrome P450 Enzymes in Glioma
Current Pharmaceutical Design Anti-Cancer Drug Design Using Natural and Synthetic Pharmacophores
Current Organic Chemistry Mechanisms of Tubulin Binding Ligands to Target Cancer Cells: Updates on their Therapeutic Potential and Clinical Trials
Current Cancer Drug Targets